IT experts call for joint AI ventures with Saudi firms in smart cities, healthcare
Business
Global Artificial Intelligence (AI) summit in Riyadh
(Web Desk) - Pakistani information technology (IT) professionals, who participated in the Global Artificial Intelligence (AI) summit in Riyadh this week, have urged local IT firms to seize opportunities in Saudi Arabia through joint ventures, highlighting a significant potential in smart city projects and the AI-driven healthcare sector in the Kingdom.
The third edition of the summit, which took place in Riyadh on September 10-12, covered important topics in the field of AI, including innovation and industry trends, to shape a brighter future and cultivate an enabling environment for technology experts.
Four distinguished Pakistani IT experts participated as thought leaders in this year’s summit, according to the Pakistani mission in Riyadh. It came at a time when Pakistan is making efforts to boost its exports, particularly in the field of IT, and attract foreign investment to cut its reliance on foreign debt to support its $350 billion economy.
“Pakistani companies have strong potential to collaborate through joint ventures in Saudi Arabia, particularly in AI-driven sectors like smart city projects and healthcare,” Tariq Khan, vice president of AI practice at Pakistan’s Visionet and Systems Group who contributed to a session, namely “Transforming Healthcare: AI’s Role in Strengthening Supply Chains,” at the summit, told Arab News over the phone from Riyadh.
“With expertise in electronics, Internet of things (IoT) and AI, Pakistan can contribute to the growing need for automation, especially as Saudi Arabia transitions its healthcare system to insurance-based models, which require extensive AI-powered documentation.”
After participating in the summit, Khan said, he gained valuable insights into the real potential of AI in the Saudi market and identified opportunities for his organization, which uses AI for diagnostic planning, discovering new biomarkers and drug discovery in the US pharmaceutical industry.
